Investor Presentaiton

Investor presentation ADA 2019 Slide 32 Progress on several projects since ADA last year June 2018 A A June 2019 Bridging strategy for semaglutide CV labels PIONEER 5, 8 and 10 results PIONEER 2, 3, 4 and 7 results STEP obesity phase 3 initiated Ziylo acquisition for accelerating glucose responsive insulin PIONEER 9 and 6 results DUAL VIII completed for XultophyⓇ OG2023 phase 1 initiated SELECT obesity CVOT phase 3 initiated REFLECT RWE trial completed for Tresiba® US filing of oral semaglutide and CV label for OzempicⓇ and oral semaglutide AM833 phase 2 initiated LAI287 phase 2 initiated EU and CA filings of oral semaglutide GLP-1 Insulin Obesity & NASH Real-World Evidence Regulatory Robin Evers SVP Medical Affairs, Regulatory Affairs & Safety Partnership with Gilead Science announced novo nordisk

View entire presentation